{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5fa6e50e5686194f10370b5d/5fa6e5164a2a5c52d1e331a5?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Clinical Implications of CGM in Patients with Type 2","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5fa6e50e5686194f10370b5d/1608154805636-877a8c65d148ab410f58219ffd02b5a8.jpeg?height=200","description":"<p>In this podcast, Dr. Roma Gianchandani from the University of Michigan identifies scenarios in which patients can benefit from ultralong-acting insulins and discuss the potential negatives of ultralong-acting insulins.</p><p>\n</p><p>Take our post-test to claim CME credits:\nPhysician <a href=\"http://dkbmedstream.com/postTestSystem/tests/index.php#351\">post-test</a>\nNurse <a href=\"http://dkbmedstream.com/postTestSystem/tests/index.php#352\">post-test</a></p><p>\n</p><p>To read a companion newsletter <a href=\"http://ediabetesreview.org/newsletters/volume-3/ediab-volume-3-issue-9.html\">click here</a>.</p><p><br></p>","author_name":"eDiabetes Review"}